Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2005

View Archived Issues

Human Genome Sciences monoclonal antibodies presented at recent congresses

Cell-based vaccine shows promise in prostate cancer

Eculizumab demonstrates long-term efficacy in paroxysmal nocturnal hemoglobinuria

Pioglitazone improves lipids more than rosiglitazone in type 2 diabetes patients

Tacrolimus ointment evaluated in allergic diseases

NeuroVax boosts FOXP3 expression in multiple sclerosis patients

Companies patent new therapies for depression, psychosis, etc.

Novel agents for the treatment of neurological disorders in early development

DA-9601 ameliorates asthma in mice

CBIQ activates mutant form of CFTR present in 75% of cystic fibrosis patients

Novel approach for asthma treatment via neurotrophin receptor antagonism

Lilly to discontinue four insulin products

NV-52 enters phase I for inflammatory bowel disease

NCI accepts Ceragenix cationic steroid antibiotic compounds for testing

Meridian Bioscience awarded license for parvovirus B19 vaccine

GlaxoSmithKline exercises option to LymphoStat

Development of ATL-146e for reperfusion injury supported by SBIR grant

PTC-124 receives orphan drug designations in Europe

Napo and Glenmark collaborate on crofelemer development

New data on gaboxadol in the treatment of primary insomnia

A gemcitabine-containing regimen improves quality of life of patients with early NSCLC

Phase II study of Prostvac-VF completes enrollment

FDA requests safety analysis for FTY-720

SPA for phase III study of Tocosol Paclitaxel in breast cancer

Sorafenib NDA filing complete

Novartis submits new Femara applications in U.S., Europe

Preos NDA accepted for review

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...